19:58 , Feb 17, 2017 |  BC Week In Review  |  Clinical News

HOST-G904: Proof-of-concept trial data

HOST reported data from an open-label, Spanish proof-of-concept (POC) trial in 20 healthy volunteers who did not have GI symptoms or a history of GI disorders and who were not required to change their diet...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

J&J, University College Cork deal

The university’s Alimentary Pharmabiotic Center’s Microbiome Institute partnered with the pharma’s Janssen Biotech Inc. unit to explore the use of viruses as treatments and/or biomarkers for inflammatory bowel disease (IBD). Janssen declined to disclose details,...
07:00 , Apr 16, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity in 1Q15 picked up where it left off at the end of last year, with 54 new partnerships disclosed, and big pharmas or biotechs accounting for 20 of those collaborations. AstraZeneca plc led...
01:34 , Jul 10, 2014 |  BC Extra  |  Financial News

Luye raises $509.8 million in Hong Kong IPO

Luye Pharma Group Ltd. (HKSE:2186) jumped HK$0.78 (13%) to HK$6.70 on its first day of trading Wednesday after raising HK$4 billion ($509.8 million) in an IPO. The company sold 667.5 million shares at HK$5.92, which...
00:04 , Jun 27, 2014 |  BC Extra  |  Financial News

Luye files for Hong Kong IPO

Luye Pharma Group Ltd. (Shanghai, China) filed for an IPO in Hong Kong and said it plans to sell 667.5 million shares at HK$5.38-HK$5.92. At the HK$5.65 midpoint, the company would raise HK$3.8 billion ($486.5...
07:00 , May 27, 2013 |  BioCentury  |  Emerging Company Profile

Calypso: Fistula fix

Calypso Biotech S.A. has mAbs against an undisclosed target to treat fistulizing Crohn's disease, a severe form of the condition that usually is refractory to marketed therapies such as immunomodulators. The company expects it will...
07:00 , Oct 29, 2012 |  BioCentury  |  Finance

Fosun's Foreign Foray

Fosun's Foreign Foray Shanghai Fosun Pharmaceuticals Group Co. Ltd. (Shanghai:600196; HKSE:02196) will use a portion of the HK$4 billion ($511.6 million) raised in its new listing on the Hong Kong Stock Exchange to go shopping abroad...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Company News

Alimentary, Norgine deal

The companies partnered to evaluate Alimentary's probiotic technology for the development of therapeutics to manage and treat gastrointestinal conditions. Norgine has an option to negotiate a license to commercialize the technology under the deal. Alimentary...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

Apriso granulated mesalamine: Phase III data

In a double-blind, U.S. Phase III trial in 305 patients with UC in remission, 1.5 g once-daily Apriso met the primary endpoint of a significantly higher proportion of relapse-free patients at 6 months vs. placebo...
07:00 , May 6, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium Not applicable A study in cell culture suggests that thuricin CD could help treat Clostridium...